Cargando…

A novel porcine model of CLN3 Batten disease recapitulates clinical phenotypes

Mouse models of CLN3 Batten disease, a rare lysosomal storage disorder with no cure, have improved our understanding of CLN3 biology and therapeutics through their ease of use and a consistent display of cellular pathology. However, the translatability of murine models is limited by disparities in a...

Descripción completa

Detalles Bibliográficos
Autores principales: Swier, Vicki J., White, Katherine A., Johnson, Tyler B., Wang, Xiaojun, Han, Jimin, Pearce, David A., Singh, Ruchira, Drack, Arlene V., Pfeifer, Wanda, Rogers, Christopher S., Brudvig, Jon J., Weimer, Jill M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Company of Biologists Ltd 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10434985/
https://www.ncbi.nlm.nih.gov/pubmed/37305926
http://dx.doi.org/10.1242/dmm.050038
Descripción
Sumario:Mouse models of CLN3 Batten disease, a rare lysosomal storage disorder with no cure, have improved our understanding of CLN3 biology and therapeutics through their ease of use and a consistent display of cellular pathology. However, the translatability of murine models is limited by disparities in anatomy, body size, life span and inconsistent subtle behavior deficits that can be difficult to detect in CLN3 mutant mouse models, thereby limiting their use in preclinical studies. Here, we present a longitudinal characterization of a novel miniswine model of CLN3 disease that recapitulates the most common human pathogenic variant, an exon 7-8 deletion (CLN3(Δex7/8)). Progressive pathology and neuron loss is observed in various regions of the CLN3(Δex7/8) miniswine brain and retina. Additionally, mutant miniswine present with retinal degeneration and motor abnormalities, similar to deficits seen in humans diagnosed with the disease. Taken together, the CLN3(Δex7/8) miniswine model shows consistent and progressive Batten disease pathology, and behavioral impairment mirroring clinical presentation, demonstrating its value in studying the role of CLN3 and safety/efficacy of novel disease-modifying therapeutics.